CD38 and Miyoshi myopathy: Interestingly, this patient’s clinical results suggested that ABBV-467 was involved in the disease stabilization of R/R MM for approximately 8 months, even though the patient was refractory to 10 prior treatment regimens, including proteasome inhibitors (ixazomib, bortezomib, and carfilzomib), immunomodulators (lenalidomide and pomalidomide), CD38 monoclonal antibody (daratumumab), SLAMF7 monoclonal antibody (elotuzumab), chemotherapy (melphalan), and corticosteroids.